Spectral Medical Inc. (TSX: EDT) invites investors to join in on the 2023 Investor Update conference call to learn more about the latest developments of the late-stage theranostic company. As a leader in advancing therapeutic options for sepsis and septic shock, Spectral has exciting news to share and is eager for the opportunity to showcase its progress.
Chris Seto, Chief Executive Officer, invites all interested parties to join him on an engaging and informative call. During the call, he will provide an overview of the topic and give participants the opportunity to ask questions and engage in meaningful dialogue. Don’t miss this opportunity to hear from the CEO and gain valuable insight into the topic at hand.
Spectral is a Phase 3 company on the brink of revolutionizing patient care with its cutting-edge product, Toraymyxin™ (“PMX”). PMX is a groundbreaking therapeutic hemoperfusion device that removes deadly endotoxin from the bloodstream and is powered by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Once approved by the U.S. FDA, PMX will be a monumental innovation for the treatment of patients with septic shock.
Spectral has secured exclusive development and commercial rights for PMX, a therapeutic product approved for use in Japan and Europe, in the U.S. and Canada. Having been used safely and effectively on more than 340,000 patients to date, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxemic septic shock in July 2022. This is a major development, as approximately 330,000 North American patients are diagnosed with septic shock each year.
Spectral Medical Inc., a leader in the medical technology field, is listed on the Toronto Stock Exchange under the symbol EDT. The company’s listing on the exchange provides investors with the opportunity to take part in Spectral’s success, as it continues to develop innovative products to improve patient outcomes.